Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts. more
Time Frame | SYRS | Sector | S&P500 |
---|---|---|---|
1-Week Return | -7.76% | 2.3% | 1.73% |
1-Month Return | -87.32% | -1.77% | 3.44% |
3-Month Return | -82.96% | -6.07% | 7.02% |
6-Month Return | -94.65% | 2.45% | 13.38% |
1-Year Return | -89.87% | 12.17% | 32.25% |
3-Year Return | -99.33% | 10.46% | 29.27% |
5-Year Return | -99.45% | 46.4% | 90.61% |
10-Year Return | -99.85% | 109.98% | 190.64% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 1.98M | 15.09M | 23.49M | 14.88M | 9.94M | [{"date":"2019-12-31","value":8.44,"profit":true},{"date":"2020-12-31","value":64.26,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":63.35,"profit":true},{"date":"2023-12-31","value":42.3,"profit":true}] |
Cost of Revenue | - | - | - | 2.97M | 2.25M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":75.9,"profit":true}] |
Gross Profit | 1.98M | 15.09M | 23.49M | 11.91M | 7.68M | [{"date":"2019-12-31","value":8.44,"profit":true},{"date":"2020-12-31","value":64.26,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":50.72,"profit":true},{"date":"2023-12-31","value":32.71,"profit":true}] |
Gross Margin | 100.00% | 100.00% | 100.00% | 80.06% | 77.33% | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":80.06,"profit":true},{"date":"2023-12-31","value":77.33,"profit":true}] |
Operating Expenses | 79.72M | 97.39M | 122.91M | 141.24M | 138.92M | [{"date":"2019-12-31","value":56.44,"profit":true},{"date":"2020-12-31","value":68.95,"profit":true},{"date":"2021-12-31","value":87.02,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":98.36,"profit":true}] |
Operating Income | (77.74M) | (82.30M) | (99.42M) | (135.87M) | (128.99M) | [{"date":"2019-12-31","value":-7774100000,"profit":false},{"date":"2020-12-31","value":-8229700000,"profit":false},{"date":"2021-12-31","value":-9942000000,"profit":false},{"date":"2022-12-31","value":-13587300000,"profit":false},{"date":"2023-12-31","value":-12898800000,"profit":false}] |
Total Non-Operating Income/Expense | - | (3.11M) | 9.04M | 39.22M | (33.90M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-7.92,"profit":false},{"date":"2021-12-31","value":23.06,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-86.43,"profit":false}] |
Pre-Tax Income | (75.44M) | (84.04M) | (86.56M) | (94.65M) | (164.57M) | [{"date":"2019-12-31","value":-7543800000,"profit":false},{"date":"2020-12-31","value":-8403800000,"profit":false},{"date":"2021-12-31","value":-8655800000,"profit":false},{"date":"2022-12-31","value":-9465400000,"profit":false},{"date":"2023-12-31","value":-16457400000,"profit":false}] |
Income Taxes | (2.30M) | 1.79M | 3.91M | (45.35M) | 2.08M | [{"date":"2019-12-31","value":-58.95,"profit":false},{"date":"2020-12-31","value":45.87,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-1160.81,"profit":false},{"date":"2023-12-31","value":53.34,"profit":true}] |
Income After Taxes | - | (85.83M) | (90.47M) | (49.30M) | (166.66M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-8583000000,"profit":false},{"date":"2021-12-31","value":-9046500000,"profit":false},{"date":"2022-12-31","value":-4930100000,"profit":false},{"date":"2023-12-31","value":-16665810500,"profit":false}] |
Income From Continuous Operations | (75.44M) | (84.04M) | (86.56M) | (94.65M) | (164.57M) | [{"date":"2019-12-31","value":-7543800000,"profit":false},{"date":"2020-12-31","value":-8403800000,"profit":false},{"date":"2021-12-31","value":-8655800000,"profit":false},{"date":"2022-12-31","value":-9465400000,"profit":false},{"date":"2023-12-31","value":-16457400000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (75.44M) | (85.83M) | (90.47M) | (49.30M) | (164.57M) | [{"date":"2019-12-31","value":-7543800000,"profit":false},{"date":"2020-12-31","value":-8583000000,"profit":false},{"date":"2021-12-31","value":-9046500000,"profit":false},{"date":"2022-12-31","value":-4930100000,"profit":false},{"date":"2023-12-31","value":-16457400000,"profit":false}] |
EPS (Diluted) | (18.90) | (18.20) | (13.80) | (12.78) | (5.76) | [{"date":"2019-12-31","value":-1890,"profit":false},{"date":"2020-12-31","value":-1820,"profit":false},{"date":"2021-12-31","value":-1380,"profit":false},{"date":"2022-12-31","value":-1278,"profit":false},{"date":"2023-12-31","value":-576,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
SYRS | |
---|---|
Cash Ratio | 2.05 |
Current Ratio | 2.25 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
SYRS | |
---|---|
ROA (LTM) | -59.88% |
ROE (LTM) | -776.96% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
SYRS | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 1.13 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -0.13 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
SYRS | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 17.44 |
P/B | 10.65 |
Price/FCF | NM |
EV/R | 22.50 |
EV/Ebitda | NM |
PEG | NM |
Syros Pharmaceuticals Inc (SYRS) share price today is $0.2675
Yes, Indians can buy shares of Syros Pharmaceuticals Inc (SYRS) on Vested. To buy Syros Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in SYRS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Syros Pharmaceuticals Inc (SYRS) via the Vested app. You can start investing in Syros Pharmaceuticals Inc (SYRS) with a minimum investment of $1.
You can invest in shares of Syros Pharmaceuticals Inc (SYRS) via Vested in three simple steps:
The 52-week high price of Syros Pharmaceuticals Inc (SYRS) is $8.17. The 52-week low price of Syros Pharmaceuticals Inc (SYRS) is $0.18.
The price-to-earnings (P/E) ratio of Syros Pharmaceuticals Inc (SYRS) is
The price-to-book (P/B) ratio of Syros Pharmaceuticals Inc (SYRS) is 10.65
The dividend yield of Syros Pharmaceuticals Inc (SYRS) is 0.00%
The market capitalization of Syros Pharmaceuticals Inc (SYRS) is $6.73M
The stock symbol (or ticker) of Syros Pharmaceuticals Inc is SYRS